PD-1 inhibitor plus anlotinib for metastatic castration-resistant prostate cancer: a real-world study

PD-1 inhibitor plus anlotinib for metastatic castration-resistant prostate cancer: a real-world study

Management and treatment of terminal metastatic castration-resistant prostate cancer (mCRPC) remains heavily debated. We sought to investigate the efficacy of programmed cell death 1 (PD-1) inhibitor plus anlotinib as a potential solution for terminal mCRPC and further evaluate the association of ge...

Full description

Bibliographic Details
Main Authors: Xin-Xing Du, Yan-Hao Dong, Han-Jing Zhu, Xiao-Chen Fei, Yi-Ming Gong, Bin-Bin Xia, Fan Wu, Jia-Yi Wang, Jia-Zhou Liu, Lian-Cheng Fan, Yan-Qing Wang, Liang Dong, Yin-Jie Zhu, Jia-Hua Pan, Bai-Jun Dong, Wei Xue
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2023-01-01
Series:Asian Journal of Andrology
Subjects:
anlotinib; ctdna; immune checkpoint inhibitor; programmed cell death-1 inhibitor; prostate cancer
Online Access:http://www.ajandrology.com/article.asp?issn=1008-682X;year=2023;volume=25;issue=2;spage=179;epage=183;aulast=Du

Internet

http://www.ajandrology.com/article.asp?issn=1008-682X;year=2023;volume=25;issue=2;spage=179;epage=183;aulast=Du

Similar Items